Hypofractionation and prostate cancer: A good option for Africa?

SA Journal of Oncology

 
 
Field Value
 
Title Hypofractionation and prostate cancer: A good option for Africa?
 
Creator Incrocci, Luca Heijmen, Ben Kupelian, Patrick Simonds, Hannah M.
 
Subject radiation oncology; urology prostate cancer; hypofractionation; Africa
Description Cancer is an emerging public health problem in Africa. According to the World Health Organization, the numbers will be doubled by 2030 because of the ageing and the growth of the population. Prostate cancer is the most common cancer among men in most African countries. Radiotherapy machines are extremely limited in Africa and therefore prostate cancer in Africa is mostly managed by urologists. However, for a large proportion of prostate cancer patients, external-beam radiotherapy (EBRT) will be the treatment of choice in Africa because of limitations of surgical expertise in many countries. The disparity between the α/β ratio for late complications and the low α/β ratio for prostate cancer widens the therapeutic window when treating prostate cancer with hypofractionation. Because of the reduced number of treatment days, hypofractionation offers economic and logistic advantages, reducing the burden of the very limited radiotherapy resources in most African countries. It also increases patient convenience. A misleading assumption is that high-level radiotherapy is not feasible in low-income countries. The gold standard option for hypofractionation includes daily image-guided radiotherapy with 3–4 implanted gold fiducials. Acceptable methods for image guidance include ultrasound and cone-beam computed tomography (CT). CT-based treatment planning with magnetic resonance imaging fusion allows for accurate volume delineation. Volumetric modulated arc therapy or inversely planned intensity modulated radiotherapy is the ideal for treatment delivery. The most vital component is safe delivery, which necessitates accurate quality assurance measures and on-board imaging. We will review the evidence and potential utilisation of hypofractionated EBRT in Africa.
 
Publisher AOSIS
 
Contributor
Date 2017-08-29
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — —
Format text/html application/epub+zip application/xml application/pdf
Identifier 10.4102/sajo.v1i0.28
 
Source South African Journal of Oncology; Vol 1 (2017); 3 pages 2523-0646 2518-8704
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajo.org.za/index.php/sajo/article/view/28/51 https://sajo.org.za/index.php/sajo/article/view/28/50 https://sajo.org.za/index.php/sajo/article/view/28/52 https://sajo.org.za/index.php/sajo/article/view/28/49
 
Coverage Africa — —
Rights Copyright (c) 2017 Luca Incrocci, Ben Heijmen, Patrick Kupelian, Hannah M. Simonds https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT